Home
>
National Drug Code (NDC)
>
Viramune
Viramune - 0597-0123-30 - (nevirapine)
Drug Information of Viramune
| Product NDC: | 0597-0123 |
| Proprietary Name: | Viramune |
| Non Proprietary Name: | nevirapine |
| Active Ingredient(s): | 400 mg/1 & nbsp; nevirapine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Viramune
| Product NDC: | 0597-0123 |
| Labeler Name: | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA201152 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20110411 |
Package Information of Viramune
| Package NDC: | 0597-0123-30 |
| Package Description: | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0123-30) |
NDC Information of Viramune
| NDC Code | 0597-0123-30 |
| Proprietary Name | Viramune |
| Package Description | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0123-30) |
| Product NDC | 0597-0123 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | nevirapine |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20110411 |
| Marketing Category Name | NDA |
| Labeler Name | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Substance Name | NEVIRAPINE |
| Strength Number | 400 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |
